Trials / Conditions / Refractory Solid Tumor

Refractory Solid Tumor

10 registered clinical trials studyying Refractory Solid Tumor — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies NCT06577987	Circle Pharma	Phase 1
Recruiting	Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression NCT06375564	The First Affiliated Hospital of Xiamen University	Phase 1
Recruiting	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Pat NCT05468359	St. Jude Children's Research Hospital	Phase 1 / Phase 2
Completed	Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors NCT05963386	The First Affiliated Hospital of Xiamen University	Phase 2
Withdrawn	Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors NCT03443622	SupremeCure Pharma Inc.	Phase 1
Completed	A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adul NCT04238819	Eli Lilly and Company	Phase 1 / Phase 2
Terminated	REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Saf NCT03690869	Regeneron Pharmaceuticals	Phase 1 / Phase 2
Terminated	ODSH + ICE Chemotherapy in Pediatric Solid Tumors NCT02164097	New York Medical College	Phase 1
Unknown	Oxaliplatin for Children With Solid Tumors NCT01558453	Sidnei Epelman	Phase 2
Completed	Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors NCT00110357	Eli Lilly and Company	Phase 1